These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 22410329

  • 1. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, Ottevanger PB, Savage PM, Massuger LF, Seckl MJ.
    Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
    [Abstract] [Full Text] [Related]

  • 2. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
    Couder F, Massardier J, You B, Abbas F, Hajri T, Lotz JP, Schott AM, Golfier F.
    Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
    [Abstract] [Full Text] [Related]

  • 3. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
    Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS.
    Gynecol Oncol; 2009 Feb; 112(2):353-7. PubMed ID: 19059633
    [Abstract] [Full Text] [Related]

  • 4. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX, Shen YM, Qian JH, Xie X.
    Zhonghua Yi Xue Za Zhi; 2005 Aug 10; 85(30):2109-12. PubMed ID: 16313819
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I, Nitecki R, Horowitz NS, Goldstein DP, de Freitas Segalla Moreira M, Elias KM, Berkowitz RS.
    Gynecol Oncol; 2018 Jan 10; 148(1):161-167. PubMed ID: 29092742
    [Abstract] [Full Text] [Related]

  • 6. [Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
    Zhou Y, Feng FZ, Xiang Y, Wan XR.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov 10; 45(11):804-7. PubMed ID: 21211275
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia.
    Kizaki S, Hashimoto K, Matsui H, Usui H, Shozu M.
    Gynecol Oncol; 2015 Dec 10; 139(3):429-32. PubMed ID: 26456138
    [Abstract] [Full Text] [Related]

  • 8. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
    Kerkmeijer LG, Wielsma S, Massuger LF, Sweep FC, Thomas CM.
    Gynecol Oncol; 2007 Jul 10; 106(1):142-6. PubMed ID: 17462723
    [Abstract] [Full Text] [Related]

  • 9. High-dose methotrexate for gestational trophoblastic disease.
    Elit L, Covens A, Osborne R, Gerulath A, Murphy J, Rosen B, Sturgeon J.
    Gynecol Oncol; 1994 Sep 10; 54(3):282-7. PubMed ID: 7522198
    [Abstract] [Full Text] [Related]

  • 10. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Hoeijmakers YM, Eysbouts YK, Massuger LFAG, Dandis R, Inthout J, van Trommel NE, Ottevanger PB, Thomas CMG, Sweep FCGJ.
    Gynecol Oncol; 2021 Dec 10; 163(3):531-537. PubMed ID: 34602288
    [Abstract] [Full Text] [Related]

  • 11. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
    Lybol C, Thomas CM, Blanken EA, Sweep FC, Verheijen RH, Westermann AM, Boere IA, Reyners AK, Massuger LF, van Hoesel RQ, Ottevanger PB.
    Eur J Cancer; 2013 Mar 10; 49(4):860-7. PubMed ID: 23099004
    [Abstract] [Full Text] [Related]

  • 12. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
    Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS.
    J Reprod Med; 2010 Mar 10; 55(7-8):279-84. PubMed ID: 20795339
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.
    Eiriksson L, Wells T, Steed H, Schepansky A, Capstick V, Hoskins P, Pike J, Swenerton K.
    Gynecol Oncol; 2012 Mar 10; 124(3):553-7. PubMed ID: 22079360
    [Abstract] [Full Text] [Related]

  • 18. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR.
    Gynecol Oncol; 2012 Jun 10; 125(3):572-5. PubMed ID: 22449733
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom.
    Taylor F, Short D, Winter MC, Tidy J, Savage PM, Sarwar N, Hancock BW, Seckl MJ, Coleman RE.
    Gynecol Oncol; 2015 Feb 10; 136(2):258-63. PubMed ID: 25542400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.